Humaniqe Biopharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 17-07-2024
- Paid Up Capital ₹ 1.10 M
as on 17-07-2024
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.22 Cr
as on 17-07-2024
- Revenue 131.50%
(FY 2023)
- Profit 43.65%
(FY 2023)
- Ebitda 75.52%
(FY 2023)
- Net Worth 98.72%
(FY 2023)
- Total Assets 70.63%
(FY 2023)
About Humaniqe Biopharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.10 M.
The company currently has active open charges totaling ₹1.22 Cr.
Modalavalasa Sireesha and Singuru Neelima serve as directors at the Company.
- CIN/LLPIN
U52100AP2019PTC112835
- Company No.
112835
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2019
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Humaniqe Biopharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Modalavalasa Sireesha  | Director | 06-Sep-2019 | Current |
| Singuru Neelima | Director | 06-Sep-2019 | Current |
Financial Performance of Humaniqe Biopharmaceuticals.
Humaniqe Biopharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 131.5% increase. The company also saw a substantial improvement in profitability, with a 43.65% increase in profit. The company's net worth Soared by an impressive increase of 98.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Humaniqe Biopharmaceuticals?
In 2023, Humaniqe Biopharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 22 Jan 2024 | ₹5.10 M | Open |
Hdfc Bank Limited Creation Date: 13 Jan 2023 | ₹6.31 M | Open |
Hdfc Bank Limited Creation Date: 23 Oct 2020 | ₹0.84 M | Open |
How Many Employees Work at Humaniqe Biopharmaceuticals?
Unlock and access historical data on people associated with Humaniqe Biopharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Humaniqe Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Humaniqe Biopharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
